HomeLUPIN • NSE
add
Lupin Ltd
Previous close
₹1,989.80
Day range
₹1,957.70 - ₹2,009.80
Year range
₹1,795.20 - ₹2,402.90
Market cap
898.43B INR
Avg Volume
1.14M
P/E ratio
24.27
Dividend yield
0.61%
Primary exchange
NSE
In the news
Financials
Income Statement
Revenue
Net income
| (INR) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 62.68B | 11.93% |
Operating expense | 30.40B | 7.93% |
Net income | 12.19B | 52.13% |
Net profit margin | 19.45 | 35.92% |
Earnings per share | 26.62 | 51.94% |
EBITDA | 16.79B | 34.15% |
Effective tax rate | 13.71% | — |
Balance Sheet
Total assets
Total liabilities
| (INR) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 29.90B | 46.96% |
Total assets | — | — |
Total liabilities | — | — |
Total equity | 172.94B | — |
Shares outstanding | 456.57M | — |
Price to book | 5.28 | — |
Return on assets | — | — |
Return on capital | 16.00% | — |
Cash Flow
Net change in cash
| (INR) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | 12.19B | 52.13% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is primarily a manufacturer of generic drugs, covering therapeutic areas such as paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis. Wikipedia
Founded
1968
Headquarters
Website
Employees
24,006
